Karuna Therapeutics (KRTX) USPTO patents

Utility

Xanomeline derivatives and methods for treating neurological disorders

27 Dec 22

James A. Monn, Clifford Adam Schlecht, Dennis A. Bennett, Giorgio Attardo

Filed: 16 Nov 20

Utility

Methods for Treating Central Nervous System Disorders with Muscarinic Receptor Activation and Antipsychotics

24 Nov 22

Provided is a method of treating a central nervous system disorder in a patient in need thereof, the method comprising co-administering a first composition comprising xanomeline and/or a salt thereof and a second composition comprising an antipsychotic.

Christian FELDER

Filed: 17 May 22

Utility

ofifqqicx0jle63har3qvpmlda0o5e4

18 Oct 22

Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.

Aimesther Betancourt, Bruce Rehlaender, Roch Thibert

Filed: 7 Jan 21

Utility

ricwglgjxm48z132tupecuybwcb

27 Sep 22

Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.

Aimesther Betancourt, Bruce Rehlaender, Roch Thibert

Filed: 3 Feb 22

Utility

jtgysstdwpzwta93fjrdwlpmwh3760bj6zabslpme06eohfce2hd

12 May 22

Provided herein are compounds of Formula I and/or salts thereof; wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22 and R23 are independently chosen from H and D.

Dennis BENNETT, Giorgio ATTARDO, Clifford SCHLECHT

Filed: 21 Feb 20

Utility

epvzedlp0g1bqn6o8pp1lbnhaspma402cba7bp89efamv yclmszyyhkhzi

17 Jun 21

Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.

Aimesther Betancourt, Bruce Rehlaender, Roch Thibert

Filed: 7 Jan 21

Utility

bz0prlwu86oy942ibsq4p0s4w5upnmexadx wpm6hta37zcw

27 May 21

Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.

Aimesther BETANCOURT, Bruce REHLAENDER, Roch THIBERT

Filed: 4 Feb 21

Utility

8e2k6p8rqy0e5yx4cp88a 3zkkx85b4cm6626bhpt5pp0bq8apxc

20 May 21

Provided herein is a method of treating schizophrenia or a disease related to schizophrenia in a patient in need thereof.

Stephen BRANNAN, Andrew MILLER

Filed: 17 Nov 20

Utility

xd6zx1l87u58 3wu5ohrzaba469fono0u0sg53tx8ltxahxx4cck90ysl

20 May 21

James A. MONN, Clifford Adam SCHLECHT, Dennis A. BENNETT, Giorgio ATTARDO

Filed: 16 Nov 20

Utility

dutntk3qm6k8kniwaap6pk3yam32p4ba5q

2 Mar 21

Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof, and a plurality of trospium beads having a core comprising a salt of trospium.

Aimesther Betancourt, Bruce Rehlaender, Roch Thibert

Filed: 27 Sep 19

Utility

o1s 0p8go2cap2elp63yoe69dpauac9ynmm6js0xplztqugv

23 Feb 21

Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.

Aimesther Betancourt, Bruce Rehlaender, Roch Thibert

Filed: 21 May 20

Utility

4hbghmjfhjggljgolfh6fso3u98yp2ldfkfe6wqmss5h9tl3

16 Sep 20

Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.

Aimesther BETANCOURT, Bruce REHLAENDER, Roch THIBERT

Filed: 20 May 20

Utility

l1ueq1mmbz0t52v3zm4nclpewj1zjnecgcl2we5

1 Apr 20

Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.

Aimesther BETANCOURT, Bruce REHLAENDER, Roch THIBERT

Filed: 26 Sep 19